Clinical validity of CTS5 for late recurrence in Chinese patients with early HR-positive breast cancer

被引：0
|
作者：
Xu, Junnnan [1 ]
Sun, Tao [1 ]
机构：
[1] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-11-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-11-18
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer
    Bae, Soong June
    Moon, Sohyun
    Kook, Yoonwon
    Baek, Seung Ho
    Lee, Minji
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    NPJ BREAST CANCER, 2025, 11 (01)
  • [2] Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
    Richman, Juliet
    Ring, Alistair
    Dowsett, Mitch
    Sestak, Ivana
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (01) : 115 - 123
  • [3] Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
    Juliet Richman
    Alistair Ring
    Mitch Dowsett
    Ivana Sestak
    Breast Cancer Research and Treatment, 2021, 186 : 115 - 123
  • [4] Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER plus breast cancer.
    Richman, Juliet
    Ring, Alistair E.
    Dowsett, Mitchell
    Sestak, Ivana
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Tajiri, Wakako
    Ijichi, Hideki
    Takizawa, Katsumi
    Koi, Yumiko
    Masuda, Takanobu
    Ueo, Hiroki
    Koga, Chinami
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Okamoto, Masahiro
    Tokunaga, Eriko
    BREAST CANCER, 2021, 28 (01) : 67 - 74
  • [6] The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Wakako Tajiri
    Hideki Ijichi
    Katsumi Takizawa
    Yumiko Koi
    Takanobu Masuda
    Hiroki Ueo
    Chinami Koga
    Yoshiaki Nakamura
    Kenichi Taguchi
    Masahiro Okamoto
    Eriko Tokunaga
    Breast Cancer, 2021, 28 (1) : 67 - 74
  • [7] Clinical relevance of clinical treatment score post 5 years (CTS5) in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial
    Bae, Soong June
    Moon, Sohyun
    Kook, Yoonwon
    Baek, Seung Ho
    Lee, Min Ji
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Usefulness of CTS5 for the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Tajiri, W.
    Masuda, T.
    Ijichi, H.
    Koga, C.
    Tanaka, J.
    Nakamura, Y.
    Okamoto, M.
    Tokunaga, E.
    BREAST, 2019, 44 : S18 - S18
  • [9] Usefulness of CTS5 for the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Tajiri, Wakako
    Sugii, Azusa
    Ijichi, Hideki
    Ueo, Hiroki
    Koga, Chinami
    Nakamura, Yoshiaki
    Okamoto, Masahiro
    Taguchi, Kennichi
    Tokunaga, Eriko
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
    Dowsett, Mitch
    Sestak, Ivana
    Regan, Meredith M.
    Dodson, Andrew
    Viale, Giuseppe
    Thuelimann, Beat
    Colleoni, Marco
    Cuzick, Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1941 - +
12345